BioCentury | Jan 4, 2019
Company News

Lee's subsidiary gets Chinese rights to Auransa's cardioprotective agent

...China Oncology Focus Ltd. received exclusive Chinese rights to preclinical candidate AU018 from AI company Auransa...
...from AI company Auransa Inc. (Palo Alto, Calif.). China Oncology Focus also gained rights to AU018...
...AU018 is a cardioprotective agent intended to be paired with chemotherapy. In human iPS cells, AU018...
BioCentury | Jan 3, 2019
Emerging Company Profile

Auransa’s AI-predicted pipeline

...covers a large percent of liver cancer patients. Auransa has also out-licensed China rights for AU018...
...OTCQX:RHHBY), Basel, Switzerland Vium Inc., San Mateo, Calif. Targets PI3K - Phosphoinositide 3-kinase Jennie Walters, Staff Writer AU018 Auransa...
Items per page:
1 - 2 of 2